Louis Aledort is a board-certified internist and hematologist who began his Mount Sinai career in 1966. A former Dean for Faculty and Hospital Affairs at Mount Sinai School of Medicine, Dr. Aledort has been The Mary Weinfeld Professor of Clinical Research in Hemophilia since 1993.
Interests: White cell disorders, Red cell disorders, Platelet disorders, Vasculitis, Thrombosis, Bleeding.
American Board of Internal Medicine
MD, Albert Einstein College of Medicine
Residency, Internal Medicine
University of Virginia Health System
University of Rochester School of Medicine & Dentistry
English, French, Yiddish
Tribute Symposium: National, Cultural, and Economic Considerations Affecting Diagnostic and Treatment Practices in Hemophilia Thoughout the Americas: A Pan-Caribbean Conference
San Juan Puerto Rico
Solomon Berson Award
Department of Nursing Life Time Achievement Award
Mount Sinai School of Medicine
proclaimed 'Lou Aledort Day'
Festschrift, presented by NHF
Department of Medicine Service Award
Mount Sinai School of Medicine
NHF Murray Thelin Science Award
Alpha Therapeutic Award
Clotting disorders, bleeding problems, von Willebrand's disease, hemophilia
The past few years have seen an explosion of scientific advances, and many have been translated into new diagnostic or therapeutic approaches to patients with disease. We have been able to continue our research efforts. We instituted testing for approximately 50% of patients with occult clotting disorders. For patients with bleeding problems, we have been able to study several new synthetic and biologic substances which can be used either prophylactically to prevent a bleeding episode or to treat one. For patients with oral surgical procedures or vaginal bleeding who cannot appropriately stop hemorrhage because of inadequate clotting factors, a novel and highly concentrated nasal spray containing a synthetic adrenaline analog has been developed and is highly successful. Our work has just led to the licensing of this new product. Several biologicals are being developed to treat a common coagulation deficiency, von Willebrand's disease. These are derived from human blood and are virally-inactivated to prevent HIV or hepatitis transmission. Four new "recombinant" factors are being studied for hemophiliacs, and we serve as a major test site. A common genetic coagulation defect found more frequently in Jewish persons of Eastern European origin has not until recently been able to be treated with a safe blood product. Such a product has been developed in England, and we serve as a national study center for this material. Hemophiliacs and von Willebrand's disease patients with and without AIDS continue to be treated at our comprehensive multi-discipline center at Mount Sinai.
Aledort L. Some Aspects on the Management of Hemophilia. Thromb Haemost 1995; 74(1): 440-443.
Schwartz JD, Aledort L, Seremetis S. Liver failure and mortality in HIV positive hemophiliacs. Haemophilia 1997; 3: 24-30.
Seremetis S. Principles of Managing Haemophiliac Bleeding. In: Forbes CD, Madhok R, Aledort L, editors. Textbook of Hemophilia. London, Chapman and Hall; 1997. pp165.
Pollman H, Aledort L. Albumin-Free Formulated Recombinant Factor VIII Preparations - How Big a Step Forward?. Thromb Haemost 1999; 82(4): 1370-1371.
Aledort L. Prophylaxis: for whom, when at what cost to patient and society?. Int Monitor on Hemophilia 1999; 7(2): 20-21.
Aledort L. Immune Tolerance Induction: Is it cost-effective? We know too little. Seminars in Thrombosis and Hemostasis 2000; 26(2): 189-193.
Aledort L. Recombinant VIIa Is a Pan-hemostatic Agent?. Thromb Haemost 2000; 83: 637-638.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Aledort during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.